ArticleJournal of molecular and cellular cardiology plus2026
Integrated heart-blood RNA editome profiling reveals circulating A-to-I editing candidates linked to dilated cardiomyopathy myocardial signatures and heart failure.
Article in Journal of molecular and cellular cardiology plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dilated cardiomyopathy (DCM) is a leading cause of heart failure (HF), yet molecular signatures that are detectable in blood and mechanistically anchored in myocardial pathology remain limited. Adenosine-to-inosine (A-to-I) RNA editing is an important post-transcriptional regulator in the heart, but its biomarker potential in human DCM and its reflection in the circulation are not well defined. Methods: We performed comprehensive RNA editome profiling of human myocardium from DCM patients and non-failing donors, and integrated these results with peripheral blood RNA editing profiles from HF patients and controls, using a SPRINT-based pipeline with stringent in-house post-postprocessing and quality filtering. Global editing distributions and site-level differential editing were assessed, and shared heart-blood candidates were evaluated for directionality and functional enrichment. Results: Cardiac RNA editing was dominated by ADAR-mediated A-to-I events and was significantly increased in DCM, with prominent enrichment in Alu elements and a higher number of unique editing sites compared with controls. Site-level analysis identified a predominantly hyper-edited DCM signature, mapping to genes and pathways linked to cardiomyopathy and cellular stress, including hypoxia and apoptosis. Cross-tissue comparison revealed 107 shared differentially edited sites between DCM heart and HF blood, with subsets showing concordant directionality. Shared targets were enriched for innate immune and type I interferon signaling, RIG-I pathway regulation, hypoxia-related responses, and apoptosis. Conclusions: DCM is associated with global myocardial A-to-I hyper-editing and a robust, multi-locus editing program. Importantly, a subset of these disease-associated editing events is detectable in peripheral blood from heart failure patients, supporting the feasibility of HF-associated circulating RNA editing signatures that reflect myocardial pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.